Episode
Case Study: How Patient Preference Data Rescued a High-Risk Device
- Podcast
- Let's Talk Risk! Podcast
- Published
- Apr 10, 2026
- Duration seconds
- 1237
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/case-study-how-patient-preference-data-rescued-a-high-risk-device/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/case-study-how-patient-preference-data-rescued-a-high-risk-device.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Imagine you are running a pivotal clinical trial for a novel implant. The data comes back, and it is rough: 80% of your patients have suffered a serious adverse event, and 40% have developed acute kidney injury. If you are sitting in the regulatory or risk management seat, you are likely drafting the project’s post-mortem. In a traditional risk management paradigm, you are preparing to tell the executive team that the device failed to meet any traditional safety threshold. But what if the FDA didn’t just approve this device, but approved it specifically because the sponsors mathematically proved that patients were willing to tolerate a higher level or risk to gain access to this device? This scenario completely dismantles the way the MedTech industry has historically viewed safety and effectiveness. As professionals, we are trained to treat clinical thresholds as objective, immutable laws of physics—a line in the sand where an adverse event rate either passes or fails. However, with the FDA’s finalized guidance issued on March 30, 2026, safety is no longer just a raw numerical threshold; it is now a quantifiable variable relative to the validated preference of the end user. So, how does a manufacturer mathematically prove that a severe safety profile is acceptable, and how does the FDA reconcile approving it? 🎧Click Play above to listen to a brief audio summary about this case and lessons QA/RA and Clinical professionals can apply in practice using the newly released FDA Guidance. In this episode, we discuss: * The fundamental difference between Patient Reported Outcomes (PROs) and Patient Preference Information (PPI)—and why conflating the two leads to flawed regulatory submissions. * The exact mechanics of how a rigorously designed Discrete Choice Experiment (DCE) re…